½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå : Á¦Ç°º°, À¯Çüº°, Åõ¿© °æ·Îº°, Àü´Þ ¸ÞÄ¿´ÏÁòº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Neoantigen Cancer Vaccine Market, By Product, By Type, By Route of Administration, By Delivery Mechanism, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1606423
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 317 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 460¾ï 5,943¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â CAGR 73.40%·Î È®´ë

½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå - ½ÃÀå ¿ªÇÐ

ȯÀÚÀÇ Ä¡·á¸¦ ¸ÂÃãÈ­Çϱâ À§ÇÑ ¸ÂÃãÇü ÀÇ·áÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ, Á¾¾ç Ư¼º, Àü¹ÝÀûÀÎ °Ç°­ »óÅ µî ȯÀÚ °³°³ÀÎÀÇ Æ¯¼º¿¡ ¸Â°Ô Ưº°È÷ °í¾ÈµÈ Ä¡·á °èȹÀ» °³¹ßÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀÇ ÇÙ½ÉÀº ȯÀÚÀÇ Á¾¾ç¿¡¼­ ¹ß°ßµÇ´Â ¶Ñ·ÇÇÑ µ¹¿¬º¯À̸¦ ±â¹ÝÀ¸·Î ¼¼½ÉÇÏ°Ô ¸¸µé¾îÁø ½ÅÇ׿ø ¹é½ÅÀÔ´Ï´Ù. ÁÖ¸ñÇÒ ¸¸ÇÑ Á¡Àº ½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â ¸ÂÃãÇü ÀǾàǰÀÇ ¼ö°¡ 132°³¿¡¼­ 286°³·Î Áõ°¡ÇßÀ¸¸ç, ÀÌ·¯ÇÑ Ä¡·á¹ýÀº 2019³â FDA°¡ ½ÂÀÎÇÑ ½Å¾àÀÇ 25%¸¦ Â÷ÁöÇÑ´Ù´Â Á¡ÀÔ´Ï´Ù.

¶ÇÇÑ Á¦¾à»ç ¹× º¥Ã³ ijÇÇÅ»ÀÇ ÅõÀÚ¸¦ Æ÷ÇÔÇÑ ¹Î°ü ¸ðµÎ·ÎºÎÅÍÀÇ ÀÚ±Ý Áö¿øÀÌ °­È­µÇ¸é¼­ ÀÌ ºÐ¾ßÀÇ ¿¬±¸°³¹ß¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ Á¦Á¶ °øÁ¤ÀÇ º¹À⼺ÀÌ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼öµµ ÀÖ½À´Ï´Ù.

½ÅÇ×¾ÏÁ¦ ¹é½Å ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¿¬Æò±Õ ¾à 73.40%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç°º°·Î´Â °³ÀÎÈ­°¡ 2023³â¿¡ °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» º¸¿´½À´Ï´Ù.

À¯Çüº°·Î´Â ÇÙ»êÀÌ 2023³â ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

¿ëµµº°·Î´Â Æó¾ÏÀÌ 2023³â ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÔ¿øÀ̾ú½À´Ï´Ù.

½ÅÇ×¾ÏÁ¦ ¾Ï ¹é½Å ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

½ÅÇ׾Ϲé½Å ¼¼°è ½ÃÀåÀº Á¦Ç°, À¯Çü, Åõ¿© °æ·Î, Àü´Þ ¸ÞÄ¿´ÏÁò, ¿ëµµ, Áö¿ªº°·Î ¼¼ºÐÈ­µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀåÀº Á¦Ç°¿¡ µû¶ó °³ÀÎÈ­(Personalized)¿Í ±â¼ºÇ°(Off-the-shelf)ÀÇ µÎ °¡Áö ºÎ¹®À¸·Î ³ª´¹´Ï´Ù. °³ÀθÂÃãÇü ºÎ¹®Àº ½ÃÀå¿¡¼­ ¾ÐµµÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. °³ÀθÂÃãÇü ½ÅÇ׿ø ¹é½ÅÀº ¸é¿ª¹ÝÀÀÀ» ³ôÀ̱â À§ÇØ PD-1, CTLA-4 ¾ïÁ¦Á¦¿Í °°Àº üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦¿Í º´¿ëÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ Á¶ÇÕ Àü·«Àº ±âÁ¸ ¸é¿ª ¿ä¹ýÀÇ ´ÜÁ¡À» ÇØ°áÇϰí ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ °ËÅäµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº À¯Çüº°·Î ¼öÁö»ó ¼¼Æ÷, ÇÙ»ê, ÇÕ¼º ·ÕÆéƼµå, Á¾¾ç ¼¼Æ÷ µî 4°¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ÇÙ»ê Ä«Å×°í¸®°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ½ÅÇ×¾Ï ¹é½Å ½ÃÀåÀº ÇÙ»ê ±â¼úÀÇ ¹ßÀü, ƯÈ÷ Á¾¾ç ƯÀÌÀû µ¹¿¬º¯ÀÌ¿¡ ´ëÀÀÇϱâ À§ÇÑ »õ·Î¿î ¹é½ÅÀÇ Ã¢Ãâ°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù.

½ÃÀåÀº Åõ¿© °æ·Î¿¡ µû¶ó ±ÙÀ°³» Åõ¿©, Á¤¸Æ³» Åõ¿©, °æÇÇ Åõ¿©ÀÇ ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ½ÅÇ׾Ϲé½Å ½ÃÀåÀº Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¸ÂÃãÇü Ä¡·áÀÇ ¹ßÀü°ú À¯ÅëÀ» À§Çؼ­´Â ´Ù¾çÇÑ Åõ¿© °æ·Î°¡ ÇʼöÀûÀÔ´Ï´Ù.

½ÃÀåÀº Àü´Þ ¸ÞÄ¿´ÏÁò¿¡ µû¶ó ¸®Æ÷¼Ø, ¹ÙÀ̷μØ, À¯ÀüÀÚ ¾Ï, ÀÏ·ºÆ®·ÎÆ÷·¹À̼Ç, ±âŸ µî 4°³ ºÎ¹®À¸·Î ºÐ·ùµË´Ï´Ù. ÀÌ·¯ÇÑ ¸ÞÄ¿´ÏÁòÀº ¸ÂÃãÇü ¹é½ÅÀ» Ç¥Àû ¼¼Æ÷¿¡ È¿°úÀûÀ¸·Î Àü´ÞÇÏ°í ¾Ï Æ¯ÀÌÀû ½ÅÇ׿ø¿¡ ´ëÇÑ °­·ÂÇÑ ¸é¿ª ¹ÝÀÀÀ» ÃËÁøÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó ³úÁ¾¾ç, ¼ÒÈ­±â¾Ï, Æó¾Ï, Èæ»öÁ¾, ±âŸ µî ³× °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Æó¾ÏÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Æó¾ÏÀÇ °æ¿ì µ¹¿¬º¯ÀÌ ºÎÇϰ¡ ³ô±â ¶§¹®¿¡ Ç¥ÀûÀÌ µÉ ¼ö ÀÖ´Â ÀáÀçÀû ½ÅÇ׿øÀÌ ´Ù¾çÇϸç, °³ÀÎ ¸ÂÃãÇü ¹é½ÅÀÌ À¯¸ÁÇÑ Á¢±Ù¹ýÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

½ÅÇ×¾ÏÁ¦ ¹é½Å ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

ºÏ¹Ì´Â źźÇÑ ÀÓ»ó½ÃÇè ÇÁ·¹ÀÓ¿öÅ©°¡ Ư¡À̸ç, ¼ö¸¹Àº ¿¬±¸ ±â°ü°ú º´¿øÀÌ ½ÅÇ׿ø ¹é½Å °³¹ß¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ±ÔÁ¦ ȯ°æÀº °£¼ÒÈ­µÈ ÀÓ»ó½ÃÇè ÇÁ·Î¼¼½º¸¦ ÃËÁøÇϰí Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ ¹ßÀü°ú Æò°¡¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ¾ÏÀÌ °ÅÀÇ ¸ðµç »ç¶÷¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ¾Ï ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø È®´ë¿¡ ´ëÇÑ ±¹¹ÎÀû ÁöÁö°¡ ³ôÀºµ¥, ÃÖ±Ù ASCO°¡ 4,000¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ ¼³¹®Á¶»ç¿¡ µû¸£¸é ¾à 73%´Â Á¤ºÎ°¡ ¼¼±Ý ÀλóÀ̳ª ±¹°¡ ÀçÁ¤ ÀûÀÚ°¡ Áõ°¡ÇÏ´õ¶óµµ ¾Ï Ä¡·á¹ý ¹× Ä¡·á¹ý ¹ß°ß¿¡ ´õ ¸¹Àº ÀÚ¿øÀ» ¹èÁ¤ÇØ¾ß ÇÑ´Ù°í ´äÇß½À´Ï´Ù. ´õ ¸¹Àº ÀÚ¿øÀ» ¹èºÐÇØ¾ß ÇÑ´Ù°í »ý°¢ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. À¯·´Àº À¯Àüü ±â¼úÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ½ÃÀå È®´ë°¡ ¿¹»óµÇ´Â µÎ ¹øÂ° Áö¿ªÀÔ´Ï´Ù. Àü¹ÝÀûÀ¸·Î ½ÅÇ׾Ϲé½ÅÀÇ ¼¼°è ȯ°æÀº Ȱ±âÂ÷°í ´Ù¾çÇÑ Áö¿ª¿¡ ¸¹Àº ¼ºÀå ±âȸ¸¦ °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù.

½ÅÇ׾Ϲé½Å ½ÃÀå - °æÀï»óȲ :

½ÅÇ׾Ϲé½Å ½ÃÀå - °æÀï»óȲ

½ÅÇ׾Ϲé½Å ½ÃÀåÀº ÁÖ¿ä ±â¾÷ÀÌ Ã·´Ü ±â¼úÀ» Àû±ØÀûÀ¸·Î Ȱ¿ëÇϰí Àü·«Àû Á¦ÈÞ¸¦ ¸ÎÀ¸¸ç ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ¸Å¿ì °æÀïÀûÀΠȯ°æÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº ¿¬±¸ ±â°ü, ÀÇ·á ½Ã¼³ ¹× ±âŸ »ý¸í°øÇÐ ±â¾÷°ú Çù·ÂÇÏ¿© ¿¬±¸°³¹ßÀ» °­È­ÇÏ°í ½ÅÇ׿ø ¹é½ÅÀÇ °³¹ßÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ²÷ÀÓ¾ø´Â ±â¼ú ¹ßÀü°ú ȯÀÚ ¿¹ÈÄ °³¼±À» À§ÇÑ ³ë·ÂÀ¸·Î ÀÎÇØ °æÀï ȯ°æÀº ºü¸£°Ô º¯È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ½Å»ýÇ׿ø ¾Ï ¹é½ÅÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å »ê¾÷ ¿¬±¸

Á¦5Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå ±¸µµ

Á¦7Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå - Á¦Ç°º°

Á¦8Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå - À¯Çüº°

Á¦9Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå - Åõ¿© °æ·Îº°

Á¦10Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå - Àü´Þ ¸ÞÄ¿´ÏÁòº°

Á¦11Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå - ¿ëµµº°

Á¦12Àå ½Å»ýÇ׿ø ¾Ï ¹é½Å ½ÃÀå - Áö¿ªº°

Á¦13Àå ÁÖ¿ä º¥´õ ºÐ¼® ½Å»ýÇ׿ø ¾Ï ¹é½Å ¾÷°è

Á¦14Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

The Neoantigen Cancer Vaccine Market size was valued at USD 46,059.43 million in 2023, expanding at a CAGR of 73.40% from 2024 to 2032.

Neoantigen cancer vaccines constitute a form of personalized immunotherapy aimed at activating the immune system to identify and combat cancerous cells. These vaccines focus on neoantigens, which are unique antigens generated from mutations within tumor cells. The development of neoantigen cancer vaccines marks a notable progression in the field of cancer immunotherapy, utilizing the distinct features of an individual's tumor to bolster the body's inherent capacity to combat cancer.

Neoantigen Cancer Vaccine Market- Market Dynamics

The growing adoption of personalized medicine aimed at customizing patient treatment is anticipated to propel market expansion. This approach emphasizes the development of treatment plans that are specifically designed to align with individual patient characteristics, such as genetic profiles, tumor features, and overall health status. Central to this methodology are Neoantigen vaccines, which are meticulously crafted based on the distinct mutations found in a patient's tumor. Notably, the number of personalized medicines available in the market increased from 132 to 286, with these therapies representing 25% of the new drugs approved by the FDA in 2019.

Moreover, enhanced funding from both public and private sectors, including contributions from pharmaceutical companies and venture capitalists, is driving research and development efforts in this domain. Nevertheless, the complexity of manufacturing processes may pose challenges to market growth.

Neoantigen Cancer Vaccine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 73.40% over the forecast period (2024-2032)

Based on Product segmentation, Personalized was predicted to show maximum market share in the year 2023

Based on Type segmentation, Nucleic Acid was the leading type in 2023

Based on Application segmentation, Lung Cancer was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Neoantigen Cancer Vaccine Market- Segmentation Analysis:

The Global Neoantigen Cancer Vaccine Market is segmented based on Product, Type, Route of Administration, Delivery Mechanism, Application, and Region.

The market is classified into two segments according to product: Personalized and Off-the-shelf. The Personalized segment holds a dominant position in the market. Personalized neoantigen vaccines are frequently used in conjunction with checkpoint inhibitors, such as PD-1 or CTLA-4 inhibitors, to enhance the immune response. This combinatorial strategy is under investigation to address the shortcomings of existing immunotherapies and to enhance patient outcomes.

The market is segmented into four categories according to type: Dendritic Cell, Nucleic Acid, Synthetic Long Peptide, and Tumor Cell. The Nucleic Acid category holds a leading position in the market. The Neoantigen Cancer Vaccine Market is significantly linked to progress in nucleic acid technologies, especially in the creation of novel vaccines aimed at addressing tumor-specific mutations.

The market is segmented into three categories according to the Route of Administration: Intramuscular, Intravenous, and Transdermal. The Neoantigen Cancer Vaccine Market is experiencing significant growth, with different routes of administration being essential for the advancement and distribution of these tailored therapies.

The market is categorized into four segments according to the Delivery Mechanism: Liposomes, Virosomes, Gene gun, Electroporation, and Others. These mechanisms are essential for effectively delivering personalized vaccines to the targeted cells, thereby facilitating a robust immune response to the cancer-specific neoantigens.

The market is segmented into four categories according to application: Brain Cancer, Gastrointestinal Cancer, Lung Cancer, Melanoma, and Others. Lung Cancer holds a leading position in the market. In the case of lung cancer, the elevated mutation burden offers a diverse range of potential neoantigens for targeting, thereby positioning personalized vaccines as a highly promising approach.

Neoantigen Cancer Vaccine Market- Geographical Insights

North America features a robust clinical trial framework, with a multitude of research institutions and hospitals engaged in the development of Neoantigen vaccines. The regulatory landscape in this region facilitates streamlined trial processes, promoting the advancement and evaluation of innovative therapies. Cancer has impacted nearly every individual in the United States, and there is significant public support for increased funding in cancer research. A recent survey conducted by ASCO, involving over 4,000 Americans, revealed that approximately 73% believe the government should allocate more resources to discovering treatments and cures for cancer, even if this necessitates higher taxes or an increase in the national deficit. Europe represents the second largest region for market expansion, driven by advancements in genomic technologies. Overall, the global environment for Neoantigen cancer vaccines is vibrant, presenting numerous growth opportunities across different regions.

Neoantigen Cancer Vaccine Market- Competitive Landscape:

The Neoantigen cancer vaccine market exhibits a highly competitive environment, with major players actively utilizing cutting-edge technologies, establishing strategic alliances, and making significant investments in research and development. These companies are collaborating with research institutions, healthcare facilities, and other biotechnology firms to strengthen their R&D efforts and accelerate the creation of neoantigen vaccines. The competitive landscape is expected to change swiftly, driven by continuous technological advancements and a commitment to enhancing patient outcomes.

Recent Developments:

On September 10, 2024, OSE Immunotherapeutics SA announced the commencement of its international Phase 3 clinical trial, named 'Artemia,' for Tedopi, a therapeutic cancer vaccine based on neoepitopes intended for off-the-shelf application. This trial is aimed at providing second-line treatment for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). The study has received review and approval from health authorities across 14 countries, including the US FDA, Canada, Europe, and the United Kingdom, marking a significant advancement in the registration process for Tedopi, in conjunction with the development of a companion diagnostic for HLA-A2 positive patients.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEOANTIGEN CANCER VACCINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY DELIVERY MECHANISM- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Neoantigen Cancer Vaccine Market Overview

2. Executive Summary

3. Neoantigen Cancer Vaccine Key Market Trends

4. Neoantigen Cancer Vaccine Industry Study

5. Neoantigen Cancer Vaccine Market: COVID-19 Impact Analysis

6. Neoantigen Cancer Vaccine Market Landscape

7. Neoantigen Cancer Vaccine Market - By Product

8. Neoantigen Cancer Vaccine Market - By Type

9. Neoantigen Cancer Vaccine Market - By Route of Administration

10. Neoantigen Cancer Vaccine Market - By Delivery Mechanism

11. Neoantigen Cancer Vaccine Market - By Application

12. Neoantigen Cancer Vaccine Market- By Geography

13. Key Vendor Analysis- Neoantigen Cancer Vaccine Industry

14. 360 Degree Analyst View

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â